News >

Expert Emphasizes Importance of Acalabrutinib Approval in MCL

Angelica Welch
Published: Thursday, Dec 14, 2017

There is an international phase III study of rituximab (Rituxan) plus or minus acalabrutinib versus placebo. Many more combinations will come in time. 

In your mission to cure MCL, what are some challenges ahead?

We must advance the science to understand the disease even better, and develop great medicines, such as ibrutinib (Imbruvica), acalabrutinib, bortezomib (Velcade), and lenalidomide (Revlimid). After a while, however, the patient will, inevitably, develop resistance. Therefore, our number 1 enemy is resistance and the only way to overcome it is through science and technology. 

What should community oncologists know about acalabrutinib now that it is commercially available?

For community oncologists and hematologists, remember the name acalabrutinib, and know it is FDA-approved for relapsed MCL—that is all they need to know. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Translating Recent Data Into Informed Sequencing Decisions in Advanced Non–Small Cell Lung CancerMar 31, 20182.0
Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 31, 20182.0
Publication Bottom Border
Border Publication